Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes

Cardiovascular (CV) outcome trials (CVOTs) of type 2 diabetes mellitus (T2DM) therapies have mostly used randomized comparison with placebo to demonstrate non-inferiority to establish that the investigational drug does not increase CV risk. Recently, several glucagon-like peptide 1 receptor agonists...

Descripción completa

Detalles Bibliográficos
Autores principales: McGuire, Darren K., D’Alessio, David, Nicholls, Stephen J., Nissen, Steven E., Riesmeyer, Jeffrey S., Pavo, Imre, Sethuraman, Shanthi, Heilmann, Cory R., Kaiser, John J., Weerakkody, Govinda J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Methodology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400320/
https://www.ncbi.nlm.nih.gov/pubmed/36002856
http://dx.doi.org/10.1186/s12933-022-01601-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400320/
https://www.ncbi.nlm.nih.gov/pubmed/36002856
http://dx.doi.org/10.1186/s12933-022-01601-w

Ejemplares similares